Risky Business: Appellate Decision Returns Endo's Generic OxyContin Case To Trial Court
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal appeals court affirms a trial court decision that Endo's product would infringe Purdue's patents.
You may also be interested in...
OxyContin Will Face Fewer Generics Following Patent Infringement Settlement
As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.
OxyContin Will Face Fewer Generics Following Patent Infringement Settlement
As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.
Watson Takes Over OxyContin "Authorized" Generic Distribution From Ivax
An earlier deal with Ivax to distribute an oxycodone controlled-release authorized generic has been terminated, Purdue says.